Iranian Journal of Neurology 2017. 16(2):83-89.

S100 B: A new concept in neurocritical care
Omidvar Rezaei, Hossein Pakdaman, Kurosh Gharehgozli, Leila Simani, Amir Vahedian-Azimi, Sina Asadi, Zahra Sahraei, Mohammadreza Hajiesmaeili


After brain injuries, concentrations of some brain markers such as S100B protein in serum and cerebrospinal fluid (CSF) are correlated with the severity and outcome of brain damage. To perform an updated review of S100B roles in human neurocritical care domain, an electronic literature search was carried among articles published in English prior to March 2017. They were retrieved from PubMed, Scopus, EMBSCO, CINAHL, ISC and the Cochrane Library using keywords including “brain”, “neurobiochemical marker”, “neurocritical care”, and “S100B protein”. The integrative review included 48 studies until March 2017. S100B protein can be considered as a marker for blood brain barrier damage. The marker has an important role in the development and recovery of normal central nervous system (CNS) after injury. In addition to extra cerebral sources of S100B, the marker is principally built in the astroglial and Schwann cells. The neurobiochemical marker, S100B, has a pathognomonic role in the diagnosis of a broad spectrum of brain damage including traumatic brain injury (TBI), brain tumor, and stroke. Moreover, a potential predicting role for the neurobiochemical marker has been presumed in the efficiency of brain damage treatment and prognosis. However further animal and human studies are required before widespread routine clinical introduction of S100 protein.


Biologic Marker; Surrogate Marker; Serum Marker; S100B Protein; Progressive Patient Care

Full Text:



Johnsson, P., Markers of cerebral ischemia after cardiac surgery. Journal of cardiothoracic and vascular anesthesia, 1996. 10(1): p. 120-126.

Vaage, J. and R. Anderson, Biochemical markers of neurologic injury in cardiac surgery: The rise and fall of S100β. The Journal of thoracic and cardiovascular surgery, 2001. 122(5): p. 853-855.

Hajiesmaeili, M., et al., Biochemical markers in Neurocritical Care. Journal of Cellular and Molecular Anesthesia, 2016. 1(3): p. 115-119.

Yardan, T., et al., Usefulness of S100B protein in neurological disorders. J Pak Med Assoc, 2011. 61(3): p. 276-281.

Green, A., et al., Increased S100β in the cerebrospinal fluid of patients with frontotemporal dementia. Neuroscience letters, 1997. 235(1): p. 5-8.

Zetterberg, H., D.H. Smith, and K. Blennow, Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nature Reviews Neurology, 2013. 9(4): p. 201-210.

Liu, W., et al., S100β in heavy metal-related child attention-deficit hyperactivity disorder in an informal e-waste recycling area. Neurotoxicology, 2014. 45: p. 185-191.

Brunnekreef, G., et al., Measurements of Cerebrospinal Fluid Concentrations of S100β Protein During and After Thoracic Endovascular Stent Grafting. European journal of vascular and endovascular surgery, 2007. 34(2): p. 169-172.

Qin, B., K.S. Panickar, and R.A. Anderson, Cinnamon polyphenols attenuate the hydrogen peroxide-induced down regulation of S100β secretion by regulating sirtuin 1 in C6 rat glioma cells. Life sciences, 2014. 102(1): p. 72-79.

Qin, B., K.S. Panickar, and R.A. Anderson, Cinnamon polyphenols regulate S100β, sirtuins, and neuroactive proteins in rat C6 glioma cells. Nutrition, 2014. 30(2): p. 210-217.

Donato, R., et al., S100B's double life: intracellular regulator and extracellular signal. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2009. 1793(6): p. 1008-1022.

Gerlach, R., et al., Active secretion of S100B from astrocytes during metabolic stress. Neuroscience, 2006. 141(4): p. 1697-1701.

de Souza, D.F., et al., S100B secretion is stimulated by IL-1β in glial cultures and hippocampal slices of rats: likely involvement of MAPK pathway. Journal of neuroimmunology, 2009. 206(1): p. 52-57.

Donato, R., S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. The international journal of biochemistry & cell biology, 2001. 33(7): p. 637-668.

Selinfreund, R.H., et al., Neurotrophic protein S100 beta stimulates glial cell proliferation. Proceedings of the National Academy of Sciences, 1991. 88(9): p. 3554-3558.

Rothermundt, M., et al., S100B in brain damage and neurodegeneration. Microscopy research and technique, 2003. 60(6): p. 614-632.

Sen, J. and A. Belli, S100B in neuropathologic states: the CRP of the brain? Journal of neuroscience research, 2007. 85(7): p. 1373-1380.

Hu, J., A. Ferreira, and L.J. Van Eldik, S100β induces neuronal cell death through nitric oxide release from astrocytes. Journal of neurochemistry, 1997. 69(6): p. 2294-2301.

Iuvone, T., et al., Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. Journal of Molecular Medicine, 2007. 85(12): p. 1379-1392.

Kerkhoff, C., M. Klempt, and C. Sorg, Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1998. 1448(2): p. 200-211.

Donato, R., Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1999. 1450(3): p. 191-231.

Hofmann, M.A., et al., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 1999. 97(7): p. 889-901.

Bianchi, R., et al., S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. Journal of Biological Chemistry, 2011. 286(9): p. 7214-7226.

Villarreal, A., et al., S100B alters neuronal survival and dendrite extension via RAGE‐mediated NF‐κB signaling. Journal of neurochemistry, 2011. 117(2): p. 321-332.

Huttunen, H.J., et al., Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. Journal of Biological Chemistry, 2000. 275(51): p. 40096-40105.

Kögel, D., et al., S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience, 2004. 127(4): p. 913-920.

Businaro, R., et al., S100B protects LAN‐5 neuroblastoma cells against Aβ amyloid‐induced neurotoxicity via RAGE engagement at low doses but increases Aβ amyloid neurotoxicity at high doses. Journal of neuroscience research, 2006. 83(5): p. 897-906.

KA, P., S100 protein family and its application in clinical practice. Hippokratia, 2008. 12(4): p. 198-204.

Gazzolo, D., et al., Human milk contains S100B protein. Biochimica et Biophysica Acta (BBA)-General Subjects, 2003. 1619(2): p. 209-212.

Kleindienst, A., et al., The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Progress in brain research, 2007. 161: p. 317-325.

Heidari, K., et al., Prediction of neuropsychological outcome after mild traumatic brain injury using clinical parameters, serum S100B protein and findings on computed tomography. Brain injury, 2015. 29(1): p. 33-40.

Nylén, K., et al., Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta neurochirurgica, 2008. 150(3): p. 221-227.

Biberthaler, P., et al., Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock, 2006. 25(5): p. 446-453.

Vos, P.E., et al., Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology, 2004. 62(8): p. 1303-1310.

Jagoda, A.S., et al., Clinical policy: neuroimaging and decisionmaking in adult mild traumatic brain injury in the acute setting. Journal of Emergency Nursing, 2009. 35(2): p. e5-e40.

Undén, J., T. Ingebrigtsen, and B. Romner, Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update. BMC medicine, 2013. 11(1): p. 1.

Lin, J., et al., Inhibition of p53 transcriptional activity by the S100B calcium-binding protein. Journal of Biological Chemistry, 2001. 276(37): p. 35037-35041.

Stranjalis, G., et al., Serum S-100B as an indicator of early postoperative deterioration after meningioma surgery. Clinical chemistry, 2005. 51(1): p. 202-207.

Ilhan-Mutlu, A., L. Wagner, and M. Preusser, Circulating biomarkers of CNS tumors: an update. Biomarkers in medicine, 2013. 7(2): p. 267-285.

Song, W., et al., [Serum S100 protein and radiation-induced brain injury in astrocytoma patients]. Di 1 jun yi da xue xue bao= Academic journal of the first medical college of PLA, 2005. 25(6): p. 723-725.

Ortiz-Munoz, B., et al., [S100 protein in tumours of the central nervous system]. Revista de neurologia, 2002. 36(11): p. 1011-1015.

Gartner, W., et al., Elevated blood markers 1 year before manifestation of malignant glioma. Neuro-oncology, 2010. 12(9): p. 1004-1008.

VOS, M.J., et al., Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer research, 2004. 24(4): p. 2511-2514.

Jauch, E.C., et al., Association of Serial Biochemical Markers With Acute Ischemic Stroke The National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Stroke, 2006. 37(10): p. 2508-2513.

Missler, U., et al., S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke, 1997. 28(10): p. 1956-1960.

Nash, D.L., M.F. Bellolio, and L.G. Stead, S100 as a marker of acute brain ischemia: a systematic review. Neurocritical care, 2008. 8(2): p. 301-307.

Purrucker, J.C., et al., Serum protein S100β is a diagnostic biomarker for distinguishing posterior circulation stroke from vertigo of nonvascular causes. European neurology, 2014. 72(5-6): p. 278-284.

Kartal, A.G., et al., Diagnostic value of S100B protein in the differential diagnosis of acute vertigo in the emergency department. Academic Emergency Medicine, 2014. 21(7): p. 736-741.

Ishibashi, H. and Y. Funakoshi, Serum S-100B protein levels in left-and right-hemisphere strokes. Journal of Clinical Neuroscience, 2008. 15(5): p. 520-525.

Foerch, C., et al., Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Archives of neurology, 2005. 62(7): p. 1130-1134.

Foerch, C., et al., Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke, 2004. 35(9): p. 2160-2164.

Delgado, P., et al., Plasma S100B level after acute spontaneous intracerebral hemorrhage. Stroke, 2006. 37(11): p. 2837-2839.

Węglewski, A., et al., Changes in the concentration of protein S100B in the blood serum of ischemic and hemorrhagic brain depending on the size of the fire percussion. Neurol. Neurochir. Pol, 2005. 39: p. 310-317.

Raabe, A., et al., S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients. Neurological research, 2004. 26(4): p. 440-445.

Fisher, C., J. Kistler, and J. Davis, Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery, 1980. 6(1): p. 1-9.

Teasdale, G., et al., A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. Journal of neurology, neurosurgery, and psychiatry, 1988. 51(11): p. 1457.

Sanchez-Peña, P., et al., S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage*. Critical care medicine, 2008. 36(8): p. 2267-2273.

Moritz, S., et al., The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. Journal of neurosurgical anesthesiology, 2010. 22(1): p. 21-31.

Weiss, N., et al., Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. The Journal of the American Society of Anesthesiologists, 2006. 104(4): p. 658-666.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.